Context: 11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity. Objectives: (i) Quantify 11β-MNT binding to androgen and progesterone receptors. (ii) Evaluate safety, tolerability, and serum gonadotropin and testosterone suppression by 11β-MNTDC in men. Design and Setting: (i) In vitro receptor binding and transactivation studies and (ii) randomized, double-blind, placebo-controlled single-dose, dose-escalating phase I study at two academic medical centers. Participants and Intervention: Twelve healthy male volunteers were randomized (five active, one placebo) to escalating single oral doses (100, 200, 400, and 800 mg) of 11β-MNTDC or placebo given with or without food. Main Outcome Measures: (i) In vitro 11β-MNT/11β-MNTDC human receptor binding and transactivation and (ii) safety and tolerability, pharmacokinetics, and quantification of serum gonadotropin and testosterone concentrations for 24 hours following dosing. Results: 11β-MNT avidly binds and activates human androgen and progesterone receptors, but 11β-MNTDC has minimal activity. Single oral doses of 11β-MNTDC were well tolerated without serious adverse events. Administration of 11β-MNTDC with food markedly increased average 11β-MNTDC and 11β-MNT serum concentrations (P < 0.001 for all doses) compared with fasting with a significant dose-related effect on average serum drug concentrations (P < 0.0001). The 200-, 400-, and 800-mg doses significantly suppressed average serum testosterone concentrations (P < 0.05). Conclusions: A single, oral dose of 11β-MNTDC up to 800 mg administered with food is safe and well tolerated in healthy men. The active drug 11β-MNT has androgenic and progestational activity, rapidly suppresses serum testosterone, and is a promising candidate for an effective once-daily oral male hormonal contraceptive.
Context: 11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity. Objectives: (i) Quantify 11β-MNT binding to androgen and progesterone receptors. (ii) Evaluate safety, tolerability, and serum gonadotropin and testosterone suppression by 11β-MNTDC in men. Design and Setting: (i) In vitro receptor binding and transactivation studies and (ii) randomized, double-blind, placebo-controlled single-dose, dose-escalating phase I study at two academic medical centers. Participants and Intervention: Twelve healthy male volunteers were randomized (five active, one placebo) to escalating single oral doses (100, 200, 400, and 800 mg) of 11β-MNTDC or placebo given with or without food. Main Outcome Measures: (i) In vitro 11β-MNT/11β-MNTDC human receptor binding and transactivation and (ii) safety and tolerability, pharmacokinetics, and quantification of serum gonadotropin and testosterone concentrations for 24 hours following dosing. Results: 11β-MNT avidly binds and activates human androgen and progesterone receptors, but 11β-MNTDC has minimal activity. Single oral doses of 11β-MNTDC were well tolerated without serious adverse events. Administration of 11β-MNTDC with food markedly increased average 11β-MNTDC and 11β-MNT serum concentrations (P < 0.001 for all doses) compared with fasting with a significant dose-related effect on average serum drug concentrations (P < 0.0001). The 200-, 400-, and 800-mg doses significantly suppressed average serum testosterone concentrations (P < 0.05). Conclusions: A single, oral dose of 11β-MNTDC up to 800 mg administered with food is safe and well tolerated in healthy men. The active drug 11β-MNT has androgenic and progestational activity, rapidly suppresses serum testosterone, and is a promising candidate for an effective once-daily oral male hormonal contraceptive.
Authors: Steve Shiraishi; Paul W N Lee; Andrew Leung; Victor H H Goh; Ronald S Swerdloff; Christina Wang Journal: Clin Chem Date: 2008-09-18 Impact factor: 8.327
Authors: Barbara J Attardi; Sheri A Hild; Sailaja Koduri; Trung Pham; Laurent Pessaint; Jean Engbring; Bruce Till; David Gropp; Anne Semon; Jerry R Reel Journal: J Steroid Biochem Mol Biol Date: 2010-06-25 Impact factor: 4.292
Authors: Bradley D Anawalt; John K Amory; Karen L Herbst; Andrea D Coviello; Stephanie T Page; William J Bremner; Alvin M Matsumoto Journal: J Androl Date: 2005 May-Jun
Authors: R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: I T Gaw Gonzalo; R S Swerdloff; A L Nelson; B Clevenger; R Garcia; N Berman; C Wang Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang Journal: J Clin Endocrinol Metab Date: 2008-02-26 Impact factor: 5.958
Authors: Anthony Yin; Eman Alfadhli; Michelle Htun; Robert Dudley; Sandra Faulkner; Laura Hull; Andrew Leung; Rachelle Bross; James Longstreth; Ronald Swerdloff; Christina Wang Journal: J Androl Date: 2012-07-12
Authors: Subarna Sinha; Merrill Knapp; John Pywtorak; Greg McCain; Kenneth Wingerden; Colin VanDervoort; J Mark Gondek; Peter Madrid; Toufan Parman; Stephen Gerrard; Jill E Long; Diana L Blithe; Stuart Moss; Min S Lee Journal: Biol Reprod Date: 2021-12-20 Impact factor: 4.161
Authors: Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang Journal: Best Pract Res Clin Obstet Gynaecol Date: 2020-02-19 Impact factor: 5.237
Authors: Fiona Yuen; Arthi Thirumalai; Cindy Pham; Ronald S Swerdloff; Bradley D Anawalt; Peter Y Liu; John K Amory; William J Bremner; Clint Dart; Hongsheng Wu; Laura Hull; Diana L Blithe; Jill Long; Christina Wang; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958
Authors: Fiona Yuen; Arthi Thirumalai; Frances A Fernando; Ronald S Swerdloff; Peter Y Liu; Youngju Pak; Laura Hull; Rachelle Bross; Diana L Blithe; Jill E Long; Stephanie T Page; Christina Wang Journal: Andrology Date: 2021-05-22 Impact factor: 4.456
Authors: Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Brian T Nguyen; Fiona Yuen; Maritza Farrant; Arthi Thirumalai; Frances Fernando; John K Amory; Ronald S Swerdloff; Bradley D Anawalt; Diana L Blithe; Jill E Long; Peter Y Liu; Stephanie T Page; Christina Wang Journal: Contraception Date: 2021-06-18 Impact factor: 3.051